Table 1.

Point prevalence and 12-month period prevalence estimate for chronic and subacute cough

	Total	Point prevalence (before exclusion)		Point prevalence (after exclusion*)		12-month period prevalence
		Count	Prevalence,%	Count	Prevalence, %	Count	Prevalence, %
Chronic cough
All respondents	24 015	694	2.89	568	2.37	1030	4.29
<60 male	7485	217	2.90	175	2.34	310	4.14
<60 female	7036	142	2.02	118	1.68	277	3.94
≥60 male	5605	216	3.85	172	3.07	273	4.87
≥60 female	3889	119	3.06	103	2.65	170	4.37
Subacute cough
All respondents	24 015	491	2.04	378	1.57	1360	5.66
<60 male	7485	204	2.73	139	1.86	492	6.57
<60 female	7036	140	1.99	120	1.71	472	6.71
≥60 male	5605	94	1.68	71	1.27	216	3.85
≥60 female	3889	53	1.36	48	1.23	180	4.63

*Respondents were excluded from the analysis if they met any of the following criteria: (1) self-reported in NHWS or the chronic cough survey of any form of lung cancer, interstitial lung disease, such as idiopathic pulmonary fibrosis, or currently taking an ACE inhibitor or (2) self-reported experienced chronic cough in the NHWS but did not participate in the chronic cough survey.

NHWS, National Health and Wellness Survey.